Literature DB >> 949874

Treatment of Goodpasture syndrome with cyclophosphamide, prednisone and plasma exchange transfusions.

R D Rossen, J Duffy, K B McCredie, M A Reisberg, J T Sharp, E M Hersh, G Eknoyan, W N Suki.   

Abstract

Repeated plasm exchanges were performed in a 44-year-old man with Goodpasture syndrome, also treated with cyclophosphamide and prednisone. Improvement was observed within 3 weeks of starting the protocol, and by the 76th week, endogenous creatinine clearance had increased from 30 to 56 ml/min/1.73 M2 and serum albumin from 2.7 to 3.7 g/dl. Prior treatment with immunosuppressive drugs had not significantly influenced circulating antibody levels. But sustained suppression of antibody was achieved after the plasma exchanges were begun, suggesting that physical removal of circulating antibody combined with antiproliferative drug treatment may be a useful way to control undesirable humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 949874      PMCID: PMC1538509     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

2.  Goodpasture's syndrome: survival after acute renal failure.

Authors:  J F Munro; A M Geddes; W L Lamb
Journal:  Br Med J       Date:  1967-10-14

3.  Goodpasture syndrome with recovery after renal failure.

Authors:  B S Strauch; A Charney; S Doctorouff; M Kashgarian
Journal:  JAMA       Date:  1974-07-22       Impact factor: 56.272

4.  Intensive plasmapheresis as a therapeutic measure in Rhesus-immunised women.

Authors:  C A Clarke; C J Elson; J Bradley; W T Donohoe; D Lehane; N C Hughes-Jones
Journal:  Lancet       Date:  1970-04-18       Impact factor: 79.321

5.  Intense plasmapheresis in the pregnant Rh-sensitized woman.

Authors:  L C Powell
Journal:  Am J Obstet Gynecol       Date:  1968-05-15       Impact factor: 8.661

6.  Carbodiimide-induced bentonite-antigen complexes: readily prepared immunoadsorbents.

Authors:  R R Carpenter; M A Reisberg
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

7.  Goodpasture's syndrome: recovery from severe pulmonary hemorrhage after bilateral nephrectomy.

Authors:  A Nowakowski; R B Grove; L H King; T T Antonovych; R W Fortner; M R Knieser; C B Carter; J H Knepshield
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

8.  Goodpasture's syndrome. Response to mercaptopurine and prednisone.

Authors:  E D Everett; K L Newcomer; J Anderson; J Bergin; E L Overholt
Journal:  JAMA       Date:  1970-09-14       Impact factor: 56.272

9.  Successful treatment of renal failure in Goodpasture's syndrome.

Authors:  J P Hayslett; J B Berte; M Kashgarian
Journal:  Arch Intern Med       Date:  1971-05

10.  Regulation of antibody formation by serum antibody. I. Removal of specific antibody by means of immunoadsorption.

Authors:  M W Graf; J W Uhr
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more
  4 in total

1.  The effect of chronic daily cyclophosphamide administration on established antibody responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

2.  Regulation of secondary antibody responses in rodents. I. Potentiation of IgG production by cyclophosphamide.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

3.  Enhancement and inhibition of immunological mechanisms by immunosuppressive agents. I. Dose effect on priming and generation of memory to a bacterial antigen.

Authors:  A J Macario; E Conway de Macario
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

4.  Goodpasture's syndrome--effects of plasmapheresis.

Authors:  Z M Munk; E Skamene
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.